Targacept, Inc. 200 East First Street, Suite 300 Winston-Salem, NC 27101-4165 Therapeutic Focus:  Central nervous system diseases and disorders Therapeutic Targets:  Neuronal nicotinic receptors (NNRs), which are key regulators of the nervous system Product Candidates:  TC-5214, major depressive disorder; AZD3480 (TC-1734), attention deficit/hyperactivity disorder (ADHD); AZD1446 (TC-6683), Alzheimer's disease; TC-5619, cognitive dysfunction in schizophrenia or one or more other indications characterized by cognitive impairment;  and TC-5685, depression/anxiety disorders.

President & CEO:  J. Donald deBethizy, Ph.D. Number of Employees:  131                                    Date Established:  March 1997 IPO Completed:  April 2006 NASDAQ Ticker Symbol:  TRGT

Strategic Alliances:

  Global collaboration and license agreement with AstraZeneca for TC-5214 for the treatment of major depressive disorder.

Exclusive global license and research collaboration with AstraZeneca AB for the development and commercialization of AZD3480 (TC-1734) to treat ADHD and AZD1446 (TC-6683) to treat Alzheimer's disease and potentially other cognitive disorders.

In addition, as of November 2007,  TC-5619 is subject to a future option of AstraZeneca for an exclusive license under the collaboration agreement.

Exclusive global strategic alliance with GlaxoSmithKline focused in five therapeutic areas: smoking cessation, pain, obesity, addiction and Parkinson's disease.

Intellectual Property:  Pentad^TM, a proprietary drug discovery platform; and an extensive patent estate covering compounds that act on NNRs